Group One Trading’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$43.3K Buy
+370
New +$37.1K ﹤0.01% 5487
2026
Q1
Sell
-872
Closed -$68.9K 8301
2025
Q4
$68.9K Buy
872
+640
+276% +$45.9K ﹤0.01% 5319
2025
Q3
$17K Buy
232
+186
+404% +$11.8K ﹤0.01% 6821
2025
Q2
$2.34K Buy
+46
New +$2.05K ﹤0.01% 7370
2023
Q4
Sell
-1,527
Closed -$46.2K 7865
2023
Q3
$48.3K Buy
1,527
+880
+136% +$24.1K ﹤0.01% 5128
2023
Q2
$16.7K Buy
647
+347
+116% +$9.23K ﹤0.01% 6100
2023
Q1
$7.21K Buy
+300
New +$6.84K ﹤0.01% 6122
2022
Q3
Sell
-500
Closed -$10K 7949
2022
Q2
$10K Sell
500
-1,500
-75% -$35.4K ﹤0.01% 6757
2022
Q1
$44K Hold
2,000
﹤0.01% 6187
2021
Q4
$32K Sell
2,000
-3,000
-60% -$46.7K ﹤0.01% 6676
2021
Q3
$100K Buy
+5,000
New +$81.3K ﹤0.01% 5911

Other funds holding MIRM

Group One Trading's MIRM Position: Q2 2026 in Review

Group One Trading opened a new position in Mirum Pharmaceuticals (MIRM) in Q2 2026: 370 shares worth $43.3K. The stake represents ﹤0.01% of the portfolio and ranks #5487 among its holdings. This is a return to the name: Group One Trading previously reported a position in MIRM as recently as Q4 2025.

Group One Trading first reported a position in MIRM in Q3 2021 and has held it in 11 quarters since. The position peaked at $100K in Q3 2021. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Group One Trading held 370 shares of Mirum Pharmaceuticals worth $43.3K as of Q2 2026.
  • Mirum Pharmaceuticals was a new Group One Trading position in Q2 2026.
  • Mirum Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5487 holding.
  • Group One Trading first reported a position in Mirum Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
  • Group One Trading's Mirum Pharmaceuticals position peaked at $100K in Q3 2021.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.